118 related articles for article (PubMed ID: 16806179)
1. Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro.
Ono K; Noguchi-Shinohara M; Samuraki M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
Exp Neurol; 2006 Nov; 202(1):125-32. PubMed ID: 16806179
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro.
Ono K; Noguchi M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
Neurobiol Dis; 2005 Nov; 20(2):233-40. PubMed ID: 16242632
[TBL] [Abstract][Full Text] [Related]
3. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Naiki H; Yamada M
J Neurosci Res; 2004 Mar; 75(6):742-50. PubMed ID: 14994335
[TBL] [Abstract][Full Text] [Related]
4. Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro.
Ono K; Hasegawa K; Naiki H; Yamada M
Biochem Biophys Res Commun; 2005 Apr; 330(1):111-6. PubMed ID: 15781239
[TBL] [Abstract][Full Text] [Related]
5. Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro.
Morinaga A; Hirohata M; Ono K; Yamada M
Biochem Biophys Res Commun; 2007 Aug; 359(3):697-702. PubMed ID: 17559807
[TBL] [Abstract][Full Text] [Related]
6. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro.
Ono K; Hirohata M; Yamada M
Biochem Biophys Res Commun; 2005 Oct; 336(2):444-9. PubMed ID: 16153607
[TBL] [Abstract][Full Text] [Related]
7. Ex situ atomic force microscopy analysis of beta-amyloid self-assembly and deposition on a synthetic template.
Ha C; Park CB
Langmuir; 2006 Aug; 22(16):6977-85. PubMed ID: 16863248
[TBL] [Abstract][Full Text] [Related]
8. The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure.
Hirohata M; Hasegawa K; Tsutsumi-Yasuhara S; Ohhashi Y; Ookoshi T; Ono K; Yamada M; Naiki H
Biochemistry; 2007 Feb; 46(7):1888-99. PubMed ID: 17253770
[TBL] [Abstract][Full Text] [Related]
9. Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro.
Ono K; Hirohata M; Yamada M
Biochem Biophys Res Commun; 2006 Mar; 341(4):1046-52. PubMed ID: 16460684
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
11. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Naiki H; Yamada M
Neurochem Int; 2006 Mar; 48(4):275-85. PubMed ID: 16343694
[TBL] [Abstract][Full Text] [Related]
12. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template.
Ha C; Ryu J; Park CB
Biochemistry; 2007 May; 46(20):6118-25. PubMed ID: 17455909
[TBL] [Abstract][Full Text] [Related]
13. Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.
Hashimoto M; Shahdat HM; Yamashita S; Katakura M; Tanabe Y; Fujiwara H; Gamoh S; Miyazawa T; Arai H; Shimada T; Shido O
J Neurochem; 2008 Dec; 107(6):1634-46. PubMed ID: 19014387
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
[TBL] [Abstract][Full Text] [Related]
15. Abeta-globulomers are formed independently of the fibril pathway.
Gellermann GP; Byrnes H; Striebinger A; Ullrich K; Mueller R; Hillen H; Barghorn S
Neurobiol Dis; 2008 May; 30(2):212-20. PubMed ID: 18353662
[TBL] [Abstract][Full Text] [Related]
16. C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells.
Trouw LA; Nielsen HM; Minthon L; Londos E; Landberg G; Veerhuis R; Janciauskiene S; Blom AM
Mol Immunol; 2008 Aug; 45(13):3649-60. PubMed ID: 18556068
[TBL] [Abstract][Full Text] [Related]
17. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation.
Crouch PJ; Tew DJ; Du T; Nguyen DN; Caragounis A; Filiz G; Blake RE; Trounce IA; Soon CP; Laughton K; Perez KA; Li QX; Cherny RA; Masters CL; Barnham KJ; White AR
J Neurochem; 2009 Mar; 108(5):1198-207. PubMed ID: 19141082
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
19. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
[TBL] [Abstract][Full Text] [Related]
20. Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease.
Montalto MC; Farrar G; Hehir CT
Ann N Y Acad Sci; 2007 Feb; 1097():239-58. PubMed ID: 17413026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
